Abstracts

The role of aflibercept in the management of diabetic macular edema.

Drug Des Devel Ther. 2015 Aug 6;9:4389-96. doi: 10.2147/DDDT.S62778. eCollection 2015.
Chang AA 1 , Hong T 2 , Ewe SY 2 , Bahrami B 2 , Broadhead GK 1 .

ABSTRACT

Diabetic macular edema (DME) represents one of the leading causes of visual impairment in working-age adults. Although there are several proven treatments available for this condition, pharmacotherapy through the use of intravitreal antivascular endothelial growth factor agents has revolutionized the management of DME over the past decade with superior outcomes compared to laser therapy. This review summarizes the pathophysiology and available treatment options for the management of DME, with an emphasis on the efficacy and safety profile of a single particular intravitreal antivascular endothelial growth factor agent, aflibercept.

http://www.ncbi.nlm.nih.gov/pubmed/26273198

OTHER Abstracts
  • Abstracts

    Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.

    Acta Ophthalmol. 2014 Dec;92(8):713-23. doi: 10.1111/aos.12463. Epub 2014 Jun 12. Broadhead GK 1 , Hong T, Chang AA.

    Read more
  • Abstracts

    Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.

    Graefes Arch Clin Exp Ophthalmol. 2015 Aug;253(8):1217-25. doi: 10.1007/s00417-014-2799-8. Epub 2014 Sep 10. Zhu M 1 , Chew

    Read more
  • Abstracts

    Dietary modification and supplementation for the treatment of age-related macular degeneration.

    Nutr Rev. 2015 Jul;73(7):448-62. doi: 10.1093/nutrit/nuv005. Epub 2015 Apr 28. Broadhead GK 1 , Grigg JR 2 ,

    Read more
More Abstracts